Organization | Butantan Institute

Butantan Institute Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Butantã Brazil (1901)

Organization Overview

First Clinical Trial

2009

NCT00981669

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Butanta Institute | Butantan Institute | Instituto butantan | Instituto Butantan

Active Ingredients

Drugs in Phase 4 Trials (2)

inactivated influenza vaccine (5 trials)

inactivated SARS-Cov-2 vaccine (4 trials)

Drugs in Phase 3 Trials (6)

bnt162b2 (Comirnaty) (2 trials)

inactivated covid-19 vaccine (1 trial)

live-attenuated chikv (1 trial)

live, attenuated, dengue serotype 1, 2, 3, 4 virus (2 trials)

ndv-hxp-s (2 trials)

split virion influenza vaccine (2 trials)

Drugs in Phase 2 Trials (6)

butantan (1 trial)

COVID-19 convalescent plasma (1 trial)

Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine (Kinrix) (1 trial)

monophosphoryl lipid a (1 trial)

ny-eso-1 peptides (1 trial)

Drugs in Phase 1 Trials (5)

aluminum hydroxide (Gaviscon) (1 trial)

gla-se (1 trial)

human rotavirus, live attenuated (Rotarix) (1 trial)

streptococcus pyogenes (1 trial)

streptococcus pyogenes vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Dengue (Phase 3)

Influenza, Human (Phase 4)

Influenza in Birds (Phase 1)

Melanoma (Phase 2)

Ovarian Neoplasms (Phase 2)

Rheumatic Fever (Phase 1)

Rotavirus Infections (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 22
# of Trial APIs: 19